Balaji Gandhi Sells 975 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 975 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $16.38, for a total transaction of $15,970.50. Following the sale, the chief financial officer directly owned 155,256 shares of the company’s stock, valued at approximately $2,543,093.28. This trade represents a 0.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Balaji Gandhi also recently made the following trade(s):

• On Friday, January 16th, Balaji Gandhi sold 4,687 shares of Phreesia stock. The shares were sold at an average price of $16.36, for a total value of $76,679.32.
• On Thursday, January 8th, Balaji Gandhi sold 8,009 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09.

Phreesia Stock Performance

NYSE PHR opened at $15.59 on Thursday. Phreesia, Inc. has a fifty-two week low of $15.40 and a fifty-two week high of $32.76. The stock has a market cap of $939.62 million, a PE ratio of -155.83 and a beta of 0.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The firm’s fifty day moving average price is $17.94 and its two-hundred day moving average price is $23.03.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. During the same period last year, the company earned ($0.25) earnings per share. The business’s quarterly revenue was up 12.7% on a year-over-year basis. On average, equities analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PHR. Canaccord Genuity Group lowered their price objective on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, December 9th. Wells Fargo & Company assumed coverage on shares of Phreesia in a research note on Thursday, January 8th. They issued an “overweight” rating and a $30.00 price objective on the stock. Barclays dropped their target price on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. BMO Capital Markets started coverage on Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective for the company. Finally, Zacks Research downgraded Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Seventeen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $30.06.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Recent operating results show improvement: Phreesia beat consensus EPS and reported revenue growth (quarterly revenue up ~12.7% year‑over‑year), supporting the business case for recovery at current multiples. MarketBeat PHR profile
• Positive Sentiment: Wall Street remains largely constructive — most analysts rate PHR a Buy and the consensus price target (~$30) is well above the current trading level, giving upside if growth continues. Analyst consensus
• Neutral Sentiment: Although insiders sold sizable blocks, each still retains a material stake after the trades (examples from filings: Evan Roberts ~826k, David Linetsky ~224k, Allison Hoffman ~170k, Balaji Gandhi ~150k, Amy Vanduyn ~159k), which may temper concerns about a loss of long‑term conviction. InsiderTrades summary
• Neutral Sentiment: Market context: volume is slightly above average and the stock is trading below its 50‑ and 200‑day moving averages and near its 52‑week low — conditions that can amplify moves but also offer a potential entry if fundamentals improve. Price performance
• Negative Sentiment: Coordinated insider selling is the primary near‑term driver of weakness: multiple senior executives sold on Jan 15–16 at ~ $16.36–$16.38 (combined ~29,511 shares). Visible, same‑period sales by several officers can prompt short‑term selling pressure as other holders react. Evan Roberts sale (example)
• Negative Sentiment: Insider sales may be interpreted as liquidity or diversification events rather than vote of no confidence, but absent clarifying disclosure (e.g., 10b5‑1 plans, option exercises) the market tends to treat clustered insider sales as a negative signal. SEC filings

Institutional Trading of Phreesia

Hedge funds have recently bought and sold shares of the business. Loomis Sayles & Co. L P acquired a new position in Phreesia during the 2nd quarter valued at about $34,162,000. Millennium Management LLC grew its holdings in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after buying an additional 936,033 shares in the last quarter. Greenhouse Funds LLLP lifted its stake in Phreesia by 16.8% during the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after acquiring an additional 557,265 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Phreesia by 1,065.9% during the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock worth $13,043,000 after acquiring an additional 506,954 shares during the last quarter. Finally, Capricorn Fund Managers Ltd bought a new stake in shares of Phreesia in the 3rd quarter worth $11,395,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.